Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome

Lancet. 1989 Sep 30;2(8666):787-9. doi: 10.1016/s0140-6736(89)90842-8.

Abstract

The effect of gamma-hydroxybutyric acid (GHB) on ethanol withdrawal syndrome in alcoholics was investigated in a randomised double-blind study. Patients with withdrawal symptoms were treated either with GHB (orally in a syrup preparation) (11 patients) or with the syrup alone (12). GHB treatment (50 mg/kg) led to a prompt reduction in withdrawal symptoms, such as tremors, sweating, nausea, depression, anxiety, and restlessness. The only side-effect was dizziness. GHB may be useful in the management of alcohol withdrawal syndrome in man.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Administration, Oral
  • Adult
  • Clinical Trials as Topic
  • Double-Blind Method
  • Drug Evaluation
  • Ethanol / adverse effects*
  • Female
  • Humans
  • Hydroxybutyrates / therapeutic use*
  • Male
  • Middle Aged
  • Random Allocation
  • Severity of Illness Index
  • Sodium Oxybate / administration & dosage
  • Sodium Oxybate / adverse effects
  • Sodium Oxybate / therapeutic use*
  • Substance Withdrawal Syndrome / drug therapy*
  • Time Factors

Substances

  • Hydroxybutyrates
  • Ethanol
  • Sodium Oxybate